Clinical Trials Logo

Metastatic Urothelial Cancer clinical trials

View clinical trials related to Metastatic Urothelial Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06225596 Recruiting - Clinical trials for Metastatic Urothelial Cancer

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Start date: January 24, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received any prior systemic therapy for locally advanced or metastatic UC and are eligible to receive platinum-based chemotherapy, whereas Cohort 2 will include participants who have received ≥ 1 prior systemic therapy for locally advanced or metastatic UC.

NCT ID: NCT05101096 Recruiting - Clinical trials for Advanced Solid Tumor

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

ASCENT-J02
Start date: October 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose (RP2D) of SG in Japanese participants with advance solid tumors. Phase 2: Evaluate the safety and efficacy of SG in Japanese participants with metastatic triple-negative breast cancer (mTNBC), hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC), and metastatic urothelial cancer (mUC).

NCT ID: NCT03745911 Recruiting - Clinical trials for Metastatic Urothelial Cancer

Paclitaxel and TAK-228 in Urothelial Carcinoma

Start date: May 4, 2018
Phase: Phase 2
Study type: Interventional

Phase II Multicentre, single arm, open label study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma (UC) and the impact of PI3K-mTOR pathway genomic alterations

NCT ID: NCT03547973 Recruiting - Clinical trials for Metastatic Urothelial Cancer

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

TROPHY U-01
Start date: August 13, 2018
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).